Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Jingzhuda (entinostat)
i
Other names:
SNDX-275, MS-275, EDP-103, KHK-2375, MS 27-275, KHK2375, SND-275, SND 275, EOC-103
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(9)
News
Trials
Company:
EOC Pharma, EddingPharm, Syndax Pharma
Drug class:
HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor
Related drugs:
‹
chidamide (23)
vorinostat (19)
panobinostat (15)
romidepsin (9)
CUDC-907 (8)
OKI-179 (4)
SB939 (4)
belinostat (2)
CG-781 (2)
MGCD0103 (2)
REC-2282 (1)
4SC-202 (1)
JNJ 26481585 (1)
CUDC-101 (0)
givinostat (0)
resminostat (0)
RG2833 (0)
sulforafan alfadex (0)
CKD-581 (0)
histone deacetylase inhibitors/hypomethylating agents (0)
CG-745 (0)
kt-3000 series (0)
kt-3283 (0)
VRx-3996 (0)
MTX110 (0)
SHP-141 (0)
OBP-801 (0)
EDO-S101 (0)
VTR-297 (0)
CXD101 (0)
purinostat (1)
chidamide (23)
vorinostat (19)
panobinostat (15)
romidepsin (9)
CUDC-907 (8)
OKI-179 (4)
SB939 (4)
belinostat (2)
CG-781 (2)
MGCD0103 (2)
REC-2282 (1)
4SC-202 (1)
JNJ 26481585 (1)
CUDC-101 (0)
givinostat (0)
resminostat (0)
RG2833 (0)
sulforafan alfadex (0)
CKD-581 (0)
histone deacetylase inhibitors/hypomethylating agents (0)
CG-745 (0)
kt-3000 series (0)
kt-3283 (0)
VRx-3996 (0)
MTX110 (0)
SHP-141 (0)
OBP-801 (0)
EDO-S101 (0)
VTR-297 (0)
CXD101 (0)
purinostat (1)
›
Associations
(9)
News
Trials
VERI cancer hierarchy
Reset Filters
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
entinostat
Resistant: B - Late Trials
entinostat
Resistant
:
B
entinostat
Resistant: B - Late Trials
entinostat
Resistant
:
B
HR positive
Breast Cancer
HR positive
Breast Cancer
entinostat
Sensitive: C2 – Inclusion Criteria
entinostat
Sensitive
:
C2
entinostat
Sensitive: C2 – Inclusion Criteria
entinostat
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
entinostat
Sensitive: C2 – Inclusion Criteria
entinostat
Sensitive
:
C2
entinostat
Sensitive: C2 – Inclusion Criteria
entinostat
Sensitive
:
C2
LDH-L
Uveal Melanoma
LDH-L
Uveal Melanoma
pembrolizumab + entinostat
Sensitive: C3 – Early Trials
pembrolizumab + entinostat
Sensitive
:
C3
pembrolizumab + entinostat
Sensitive: C3 – Early Trials
pembrolizumab + entinostat
Sensitive
:
C3
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
entinostat
Sensitive: D – Preclinical
entinostat
Sensitive
:
D
entinostat
Sensitive: D – Preclinical
entinostat
Sensitive
:
D
FBXW7 mutation
Squamous Cell Carcinoma of Head and Neck
FBXW7 mutation
Squamous Cell Carcinoma of Head and Neck
entinostat
Sensitive: D – Preclinical
entinostat
Sensitive
:
D
entinostat
Sensitive: D – Preclinical
entinostat
Sensitive
:
D
PAX3-FOXO1 fusion
Rhabdomyosarcoma
PAX3-FOXO1 fusion
Rhabdomyosarcoma
entinostat
Sensitive: D – Preclinical
entinostat
Sensitive
:
D
entinostat
Sensitive: D – Preclinical
entinostat
Sensitive
:
D
CDH1 deletion
Breast Cancer
CDH1 deletion
Breast Cancer
entinostat
Sensitive: D – Preclinical
entinostat
Sensitive
:
D
entinostat
Sensitive: D – Preclinical
entinostat
Sensitive
:
D
CDH1 deletion
Gastric Cancer
CDH1 deletion
Gastric Cancer
entinostat
Sensitive: D – Preclinical
entinostat
Sensitive
:
D
entinostat
Sensitive: D – Preclinical
entinostat
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login